Market research
1548.HK Genscript Biotech Corporation
Current ticker: 1548.HK
HK HKD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 72B
- P/E ratio
- Not available
- Analyst target
- 32.916
- Dividend yield
- Not available
- Beta
- 0.81
Profile
Instrument facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KYG3825B1059
- Market cap
- 72B
- P/E ratio
- Not available
- Analyst target
- 32.916
- Dividend yield
- Not available
- Beta
- 0.81
About
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Research context
Genscript Biotech Corporation appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 1548.HK discussion.
5 years, 7 months ago
Genscript Biotech Corporation is currently in a long term uptrend where the price is trading 118.2% above its 200 day moving average.
From a valuation standpoint, the stock is 91.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.4.
Genscript Biotech Corporation's total revenue rose by 48.2% to $224M since the same quarter in the previous year.
Its net income has dropped by 32.0% to $-92M since the same quarter in the previous year.
Finally, its free cash flow fell by 18.8% to $-59M since the same quarter in the previous year.
Based on the above factors, Genscript Biotech Corporation gets an overall score of 3/5.